Quince Therapeutics, Inc.
NASDAQ: QNCX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dirk Thye
- Employees
- 36
- Headquarters
- South San Francisco, United States
- IPO year
- 2019
- Market cap
- $5.3M
- Website
- https://www.quincetx.com
Loading QNCX…
Loading profile data…Frequently asked questions about QNCX
What does Quince Therapeutics, Inc. (QNCX) do?
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large...
Where does QNCX trade?
Quince Therapeutics, Inc. (QNCX) trades on the NASDAQ Global Select.
What sector is QNCX in?
Quince Therapeutics, Inc. (QNCX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Quince Therapeutics, Inc.?
Dirk Thye is the chief executive officer of Quince Therapeutics, Inc. (QNCX).
Where is Quince Therapeutics, Inc. headquartered?
Quince Therapeutics, Inc. is headquartered in United States.
Does QNCX pay a dividend?
Quince Therapeutics, Inc. (QNCX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did QNCX go public?
Quince Therapeutics, Inc. (QNCX) completed its initial public offering in 2019.